Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887410 | 0.87 | TSHR (0.47) | HRH4HRH3TSHRL3MBTL1TP53 | |
| SCHEMBL4901240 | 0.79 | HRH4 (0.44) | HRH4HRH3ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL6971912 | 0.71 | HRH3 (0.51) | HRH4HRH3ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL20470604 | 0.71 | ALDH1A1 (0.51) | HRH4HRH3ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL28814422 | 0.70 | — | — | |
| SCHEMBL8798036 | 0.70 | TAAR1 (0.57) | HRH4HRH3ALDH1A1TSHRHCAR2 | |
| SCHEMBL14458204 | 0.70 | TP53 (0.54) | TSHRL3MBTL1TDP1NAAATP53 | |
| SCHEMBL19987777 | 0.69 | RAB9A (0.42) | HRH4HRH3ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL338572 | 0.68 | — | — | |
| SCHEMBL1066576 | 0.68 | TSHR (0.67) | HRH4HRH3ALDH1A1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | PFIZER INC. (US) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | SPR, TPMT, IMPDH1 | HRH4 530/4885HRH3 621/4885ALDH1A1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.